Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue File

16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

Estimated average burden

3235-0287

2014

0.5

December 31,

OMB Number:

Expires:

hours per

response

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading Symbol 1. Name and Address of Reporting Person^{*} 5. Relationship of Reporting Person(s) to CRYOLIFE INC [CRY] Issuer Mackin James P (Check all applicable) 3. Date of Earliest Transaction (Month/Day/Year) Director 10% Owner 02/19/2015 (First) (Last) (Middle) Officer (give Other (specify Х CRYOLIFE, INC., 1655 ROBERTS BLVD, NW title below) below) President & CEO (Street) 4. If Amendment, Date of Original Filed 6. Individual or Joint/Group Filing (Check KENNESAW GA 30144 (Month/Day/Year) Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting (City) (State) (Zip) Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership		
			Code	v	Amount	(A) or (D)	Price	Following Reported Transaction(s) (Instr. 3 and 4)	or Indirect (I) (Instr. 4)	(Instr. 4)		
Common Stock	02/19/2015		А		30,832 (1)	Α	\$ 11	280,832	D			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Instr. 8		of and		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$ 11	02/19/2015		A		85,105		02/19/2016 ⁽²⁾	02/19/2022	Common Stock	85,105	\$0	85,105	D	

Explanation of Responses:

1. Represents shares of restricted stock that vest on the third anniversary of the grant date if the reporting person remains in the continuous employ of the Company.

2. Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date (February 19, 2015).

/s/ D. Ashley Lee, Attorneyin-fact 02/20/2015

Flace

** Signature of Reporting Date Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

CONFIRMING STATEMENT

This Statement confirms that the undersigned has authorized and designated the Chief Financial Officer, Secretary, or the Assistant Secretary of CryoLife, Inc. to execute and file on the undersigned's behalf all Forms 3, 4 and 5 (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange commission as a result of the undersigned's ownership of or transactions in securities of CryoLife, Inc. The authority of the Chief Financial Officer, the Secretary, or the Assistant Secretary of CryoLife, Inc. under this Statement shall continue until the undersigned is no longer required to file Forms 3, 4 and 5 with regard to the undersigned's ownership of or transactions in securities of CryoLife, Inc., unless earlier revoked in writing. The undersigned acknowledges that the Chief Financial Officer, the Secretary, or the Assistant Secretary of CryoLife, Inc. is not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

Dated as of September 2, 2014

/s/ James P. Mackin James Patrick Mackin